Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Prof Ahmed Ahmed and Prof Enzo Cerundolo, winners of the Ovarian Cancer Action International Grand Challenge Award.

Painting of the fallopian tubes © Susan Lockhart CC BY-NC

The £600,000 award will support research on new ways to enhance immune responses for the treatment of ovarian cancer.

Around 7,500 women are diagnosed with ovarian cancer in the UK each year, making it the 6th most common cancer in women. A significant proportion of ovarian cancers harbour tumour infiltrating lymphocytes, suggesting that immunotherapy strategies might improve prognosis. However, checkpoint inhibitor therapies have so far been of limited success, in contrast with other types of cancers such as melanoma. There is therefore an unmet need for the development of complimentary immunotherapeutic strategies.

The project now funded by Ovarian Cancer Action aims to establish a translation-ready therapeutic platform for treating ovarian cancer patients. The project will focus on adoptive T cell therapies, where patient T cells are expanded in vitro and then re-administered to the patient, with the aim of enhancing the immune response to the tumour. Adoptive T cell therapies have shown great promise in ovarian cancer, but specificity and efficacy are still lacking. This project will specifically look at the selection, isolation and expansion of neo-epitope-specific T cells, and will take advantage of the Cerundolo group’s expertise on immunotherapy and the Ahmed group’s work on ovarian cancer genomics and human organoids.

“We are very excited for winning this award. This work will enable us to investigate novel immunotherapeutic approaches for treating ovarian cancer patients.” said Prof Ahmed. The announcement was made at the Ovarian Cancer Action Research Awards Ceremony last week, hosted by the Royal College of Obstetricians and Gynaecologists.

A PhD studentship is currently available to contribute to this project, with an application deadline of the 10th of January. Prospective applicants can find more information about this opportunity here.

 

Prof Ahmed receives the first installment of his Ovarian Cancer Action AwardProf Ahmed receives the first installment of his Ovarian Cancer Action Award

 

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.